Business
Treace Medical Concepts Reports First Quarter 2025 Financial Results
PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over
About this update from Treace Medical Concepts, Inc.
[{"type":"image","alt":"Treace Medical Concepts, Inc.","displaySize":"","headline":null,"caption":"Treace Medical Concepts, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/d629ef51169cbf34a252b8eca6fa7363"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vLorRmISLl3PfaqwwnfXfQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d629ef51169cbf34a252b8eca6fa7363","width":300,"height":60}},"lazy":false},{"type":"text","content":"PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025.","length":434,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in the first quarter 2025 compared to $(8.3) million in the same period in 2024.","length":249,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded bunion technology portfolio through limited market releases of the Nanoplasty™ and the Percuplasty™ 3D MIS Osteotomy Systems, and the SpeedMTP™ MTP Fusion System, with additional launches expected in 2025.","length":214,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced positive interim clinical data for Lapiplasty, Mini Lapiplasty, and Adductoplasty procedures, at the 2025 ACFAS Annual Scientific Conference.","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Broadened global patent portfolio surpassing 100 granted patents in addition to 172 pending patent applications.","length":112,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":838,"olType":false},{"type":"text","content":"“We...